As part of a tour of the exhibition area of the BioHabana 2022 International Congress, where products from the BioCubaFarma business group are exhibited, the official considered highly the progress made in this area.
As he revealed, these are even more outstanding considering the obstacles imposed by the economic, financial and commercial blockade of the United States against the island for more than six decades.
“That is why we remain firm in condemning the blockade, because the world opposes that policy, and because what this country has done for many states during the pandemic speaks of the generosity that José Martí set as an example and Fidel Castro promoted”, he claimed.
We have been impressed with what has been happening in Cuba over the last decades, with its indomitable spirit, its intellectual capacity and its commitment to self-determination and hard work, he added.
Finally, Skerrit thanked Eduardo Martínez, president of BioCubaFarma, for all the efforts that the Antillean territory deploys for the benefit of humanity.
The Prime Minister’s statements came after the signing of an agreement for the commercialization of the Cuban drug Heberprot-P, intended for the treatment of patients with diabetic foot ulcers.
The document was signed by the Minister of Youth Development and Empowerment of Dominica, Adys King, and the Deputy Director General of the Center for Genetic Engineering and Biotechnology of Cuba, Dr. Jorge Valdés.
According to statements by officials of the scientific institution, this constitutes a base document to subsequently proceed with the registration and supply of this drug to the Caribbean country, and also in pursuit of training human resources in relation to its use.
The BioHabana 2022 Congress, which is in session from yesterday until next Friday the 29th, brings together delegates and guests from 51 countries at the Havana Convention Center.
At the meeting, 10 fundamental topics are discussed, among which medical technology and industry 4.0, chronic inflammation, cancer and autoimmunity, agricultural biotechnology and brain diseases stand out.
ef/car/ifs
